Regulatory Approval

Georgia Power received regulatory approval for a major capacity expansion, adding 9,900 MW of diverse generation resources. This plan, agreed upon with the Public Interest Advocacy Staff, aims to meet Georgia’s growing energy demand while providing an estimated $556 million in annual savings for residential customers. The company is also freezing base rates through 2028, with large-load customer revenue contributing to lower costs for families and small businesses.

Zefiro Methane Corp. (OTCQB: ZEFIF) settled CAD 407,856 of debt with two creditors on Nov 28 2025. The company will issue 1,127,273 common shares at a CAD 0.275 deemed price and grant 400,000 stock options exercisable at CAD 0.40, each expiring in one year. An additional CAD 97,856 of debt is forgiven without consideration. All issuances are subject to a four‑month‑plus‑one‑day hold period and CBOE Canada approval, potentially diluting existing shareholders but strengthening the balance sheet for growth in the methane‑abatement market.

Hang Feng Technology Innovation (NASDAQ: FOFO) announced that its subsidiary Hang Feng International Asset Management obtained SFC approval to upgrade its Type 4 and Type 9 licences, enabling it to provide virtual‑asset advisory and portfolio‑management services to professional investors. The upgrade permits advice on crypto assets and managing portfolios with over 10% virtual‑asset exposure, supporting Hang Feng’s digital‑asset strategy and targeting institutional demand in Hong Kong’s regulated market. The firm expects virtual‑asset services to contribute up to 15% of revenue by 2027.

NervGen Pharma announced positive Q3 2025 results highlighting progress in the CONNECT SCI study, where NVG-291 showed clinically meaningful improvements in spinal cord injury patients versus placebo. 75% of the NVG-291 group reported global improvement compared to 33% in the placebo arm. The FDA confirmed potential regulatory pathways for NVG-291, with an End-of-Phase 2 meeting planned for early 2026. A $10.05M private placement was completed. Cash reserves stood at $11.4M. Preclinical data showed promise in hearing loss and nerve injury models.

Rapid Dose Therapeutics (RDTCF) extended its agreement with an international partner to evaluate its NicStrip™ oral thin film nicotine delivery system. The seven-month extension is valued at $1.8M CAD. RDT filed for Health Canada approval for NicStrip™ in multiple dosages and initiated a clinical study comparing it to traditional cigarettes. Two patent applications were filed covering dissolvable and non-dissolvable formats. NicStrip™ targets adult consumers seeking smoke-free alternatives. Market trends show significant growth in nicotine pouches and other modern oral nicotine products.

Vistra (VST) received FERC approval to acquire seven natural gas generation facilities from Lotus Infrastructure Partners, adding approximately 2,600 megawatts to its portfolio. The facilities, located across PJM, New England, New York, and California, will enhance Vistra’s power generation capabilities and grid reliability. The deal is expected to close by Q1 2026, pending standard conditions and NYPSC approval. Analysts see the acquisition as aligning with Vistra’s strategy to optimize its generation fleet and capitalize on natural gas demand. The acquired facilities represent modern, efficient natural gas assets, potentially positively impacting Vistra’s earnings.

Sandstorm Gold’s acquisition by Royal Gold has secured key regulatory approvals, pending shareholder and court approvals, and Nasdaq listing. The deal, expected to close early Q4 2025, aims to diversify Royal Gold’s portfolio and enhance growth. Analysts foresee potential synergies from combining Royal Gold’s infrastructure with Sandstorm’s royalty portfolio, leading to cost efficiencies and greater financial capacity. Sandstorm shareholders are urged to vote on the arrangement by October 7, 2025, with online voting encouraged due to potential postal disruptions. Sandstorm holds interests across 40 operating mines and has approximately 230 royalties.

Gilead Sciences’ Yeytuo^® (lenacapavir), a twice-yearly injectable HIV-1 capsid inhibitor, has received European Commission (EC) approval for pre-exposure prophylaxis (PrEP). This marks the first and only twice-yearly PrEP option available in the EU, plus Norway, Iceland, and Liechtenstein. Backed by Phase 3 PURPOSE 1 and 2 trial data showing high efficacy, the EC decision follows FDA approval and WHO recommendations. This approval aims to address unmet needs in HIV prevention, particularly among vulnerable populations, and accelerate progress toward ending the HIV epidemic in Europe.

Elon Musk announced on X that Tesla may enable in-car gaming while driving within 3-6 months, pending regulatory approval. This follows a video of a Tesla owner playing Grand Theft Auto using Full Self-Driving (FSD). While presenting a potential revenue stream via subscriptions, the plan faces significant regulatory hurdles due to safety concerns and driver distraction, even with FSD engaged. Tesla emphasizes that drivers must remain vigilant and ready to take control despite FSD.